Abstract
Blood eosinophil counts which were once regarded as normal, have become of increasing interest in the era of Interluekin-5 (IL-5) asthma treatment. Blood eosinophils as low as 150 cells/μL have been suggested as treatment cut-offs for eosinophil depleting therapies such as mepolizumab [1], whilst a value of 300 cells/μL has been deemed a more pragmatic cut off by the National Institute for Health and Care Excellence (United Kingdom). In this era of eosinophil post-truths, inhaled corticosteroids (ICS), the eosinophil's oldest adversary, are very much the forgotten man.
This article is protected by copyright. All rights reserved.
http://ift.tt/2AnR7XQ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου